Cybin, Inc. HELP 深 沪
等待开盘 03-25 09:30:00 美东时间
4.51
-0.030
-0.66%
华盛通- 最 高4.58
- 今 开4.52
- 成交量 45.43万股
- 最 低 4.41
- 昨 收 4.54
- 总市值 2.26亿
- 52周最高 9.83
- 市盈率 静 --
- 换手率 0.91%
- 52周最低 4.41
- 委 比 44.98%
- 总股本 5003.58万
- 历史最高 122.36
- 量 比 0.76
- 振 幅 3.74%
- 历史最低 4.41
- 每 手 1
- 风险率 0.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
Issued on behalf of Cybin D/B/A Helus Pharma USANewsGroup.com News Commentary VANCOUVER, BC, March 9, 2026 /PRNewswire/ -- The central nervous system therapeutics sector is approaching a com...
03-09 22:50
Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints
Helus Pharma (Cybin) shares fall after Phase 2 anxiety drug results show symptom improvement, but pressure on the stock.
03-05 23:38
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
HC Wainwright & Co. Maintains Buy on Helus Pharma, Raises Price Target to $95
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Helus Pharma (NASDAQ:HELP) with a Buy and raises the price target from $55 to $95.
03-02 22:04
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
Issued on behalf of Helus Pharma VANCOUVER, BC, Feb. 26, 2026 /PRNewswire/ -- USA News Group News Commentary – The first psilocybin compound to achieve two positive Phase 3 results in treatm...
02-27 01:07
Helus Pharma Announces Publication In Nature Medicine Of Results From Phase 2a Randomized, Placebo-Controlled Clinical Trial Evaluating SPL026, In Participants With Moderate-To-Severe MDD
Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive symptoms as measured by MADRS score (mean difference: -7.35) versus placebo
02-17 20:38
Helus Pharma Q3 EPS $(1.00) Misses $(0.80) Estimate
Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.80) by 25 percent. This is a 164.55 percent decrease over losses of $(0.38) per share from the
02-13 20:40
Helus PharmaTM Appoints Michael Cola CEO, Effective Immediately
Helus PharmaTM ("Helus") (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced the appointment of
02-10 20:34
